Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Non-Current Assets of $392000.0 for Q1 2026, down 6.67% sequentially from $420000.0 in Q4 2025, and down 9.89% YoY from $435000.0 in Q1 2025.
Mineralys Therapeutics (MLYS) Non-Current Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $392000.0 in Q1 2026.
- Quarterly Non-Current Assets fell 9.89% year-over-year to $392000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 29.06% YoY) and the FY2025 annual result came in at $420000.0, down 23.91% from the prior year.
- Non-Current Assets retreated to $392000.0 in Q1 2026 per MLYS's latest filing, from $420000.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $31.2 million in Q1 2023 and troughed at $151000.0 in Q3 2025.
- A 5-year average of $5.2 million and a median of $506000.0 in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets jumped 55.3% in 2023, then sank 98.62% in 2024.
- Over 5 years, Non-Current Assets stood at $1.6 million in 2022, then soared by 55.3% to $2.5 million in 2023, then tumbled by 78.21% to $552000.0 in 2024, then fell by 23.91% to $420000.0 in 2025, then slipped by 6.67% to $392000.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $392000.0, $420000.0, and $151000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 2.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.05 Mn |
| Mar 31, 2026 | 392,000.00 |
| Dec 31, 2025 | 420,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 455,000.00 |
| Mar 31, 2025 | 435,000.00 |
| Dec 31, 2024 | 552,000.00 |
| Sep 30, 2024 | 521,000.00 |
| Jun 30, 2024 | 491,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | 12.18 Mn |
| Jun 30, 2023 | 21.73 Mn |
| Mar 31, 2023 | 31.16 Mn |
| Dec 31, 2022 | 1.63 Mn |